home / stock / bicx / bicx news

BICX News and Press, BioCorRx Inc. From 03/16/22

Stock Information
Company Name: BioCorRx Inc.
Stock Symbol: BICX
Market: OTC
Website: biocorrx.com
Menu
BICX BICX Quote BICX Short BICX News BICX Articles BICX Message Board
Get BICX Alerts

News, Short Squeeze, Breakout and More Instantly...
BICX - BioCorRx gets review board nod to begin phase 1 trial of BICX104 for opioid use disorder

BioCorRx (OTCQB:BICX) received approval from an independent institutional review board to begin a phase 1 trial of its therapy BICX104, an implantable biodegradable naltrexone pellet to treat opioid use disorder. Naltrexone is used to manage alcohol or opioid use disorder by re...
BICX - BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Independent Instit...

BICX - BioCorRx to Present at the Q1 Investor Summit Conference on March 9th

Anaheim, California--(Newsfile Corp. - March 2, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will present at the Q1 Investor Summit, hosted by the Inve...

BICX - BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104

ANAHEIM, CA - ( NewMediaWire ) - February 14, 2022 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, is pleased to announce that it has completed its clinical trial agreement w...
BICX - BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference

ANAHEIM, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO ...

BICX - BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board

ANAHEIM, CA - ( NewMediaWire ) - December 09, 2021 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory ...

BICX - BioCorRx to Participate in the Benzinga All Access Event on December 2nd

ANAHEIM, CA - ( NewMediaWire ) - November 24, 2021 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioC...
BICX - BioCorRx acquires Intellectual Property for drug delivery

BioCorRx (OTCQB:BICX) has acquired a patent application from Calista Therapeutics. This IP complements the company’s current IP portfolio and may be used for improvements to current naltrexone formulations owned by the company or licensed to third parties for use with other molecu...

BICX - BioCorRx Acquires Intellectual Property for Drug Delivery

Patent Application Covers Solid Implant Formulation for Drug Delivery ANAHEIM, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance ...

BICX - BioCorRx Provides Business Update for the Third Quarter of 2021

ANAHEIM, CA - ( NewMediaWire ) - November 16, 2021 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September ...
Previous 10 Next 10